SIA
ABBV icon

SGL Investment Advisors’s AbbVie ABBV Stock Holding History

SGL Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$967K Buy
3,901
+377
+11% +$81.1K 0.33% 63
2026
Q1 		$715K Sell
3,524
-354
-9% -$78.5K 0.27% 77
2025
Q4 		$849K Buy
3,878
+296
+8% +$67.4K 0.34% 65
2025
Q3 		$759K Buy
3,582
+1,761
+97% +$359K 0.32% 66
2025
Q2 		$346K Buy
1,821
+120
+7% +$22.3K 0.16% 94
2025
Q1 		$316K Buy
1,701
+440
+35% +$85.5K 0.16% 86
2024
Q4 		$243K Buy
+1,261
New +$232K 0.12% 103

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SGL Investment Advisors's ABBV Position: Q2 2026 in Review

SGL Investment Advisors increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $81.1K and bringing the position to 3,901 shares worth $967K. The position accounts for 0.33% of the portfolio, ranked #63.

SGL Investment Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • SGL Investment Advisors held 3,901 shares of AbbVie worth $967K as of Q2 2026.
  • SGL Investment Advisors bought 377 AbbVie shares in Q2 2026, an estimated $81.1K.
  • AbbVie made up 0.33% of SGL Investment Advisors's portfolio in Q2 2026, its #63 holding.
  • SGL Investment Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SGL Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.